0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Neurology |

Highlights FREE

JAMA Neurol. 2016;73(1):5. doi:10.1001/jamaneurol.2015.2431.
Text Size: A A A
Published online

RESEARCH

Farlow and colleagues identify genetic variants contributing to disease risk in familial Parkinson disease (PD). They identify genes containing rare, likely deleterious, genetic variants in individuals with familial PD using a 2-stage exome sequencing study design. TNK2 and TNR harbored rare, likely deleterious, variants in individuals having familial PD, with similar findings in an independent cohort. Mathias Toft, MD, PhD, and Owen A. Ross, PhD, provide an editorial.

Eisenmenger and colleagues assess the natural history of the magnetic resonance imaging (MRI) signal abnormalities on diffusion-weighted imaging (DWI) in sporadic Creutzfeldt-Jakob disease (CJD) to improve our understanding of the pathogenesis and to investigate the potential of DWI as a biomarker of disease progression, with histopathological correlation. They correlated regional and total brain scores with disease duration. They report that DWI in the basal ganglia may provide a noninvasive biomarker in future therapeutic trials.

Petersen and coauthors explore the effect of elevated amyloid levels on subsequent changes in cognition and biomarkers. Cognitive measures of memory, language, attention/executive function, visuospatial skills, Pittsburgh Compound B levels, hippocampal and ventricular volumes, and fluorodeoxyglucose positron emission tomography measures were obtained. They find that elevated amyloid levels at baseline were associated with worse cognition and imaging biomarkers at baseline and with greater clinical decline and neurodegeneration in persons selected from a population-based study.

The Huntington Study Group PHAROS Investigators identify the earliest features associated with the motor diagnosis of Huntington disease (HD) in the Prospective Huntington at Risk Observational Study (PHAROS). They compared HD mutation status in individuals with cytosine-adenine-guanine (CAG) expansion vs those without CAG expansion. They conclude that relatively large treatment effects would be required to mount a randomized, placebo-controlled clinical trial involving premanifest HD individuals who carry the CAG expansion.

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,325 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs